Clinical Trial

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 28, 2026 (before its estimated May 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of different doses of RS-113 versus abiraterone, as well as to investigate pharmacokinetics profile and to perform a pilot evaluation of pharmacokinetics parameters of RS-113 in patients with metastatic castration-resistant prostate cancer
Trial Details
NCT Number NCT07553988
Lead Sponsor R-Pharm International, LLC
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 120 participants
Start Date 2024-10-24
Primary Completion 2026-05-14 (estimated)
Study Completion 2027-05-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-28